Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
2 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Ensysce Biosciences, Inc.’s names, not what it holds today.
Patents granted
2
2 utility, 1976 to Dec 31, 2025
Granted in 2025
1
in the last year the record reads
Applications published
10
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Ensysce Biosciences Inc. its own name
named as the applicant on its applications, in US
7 publishedEnsysce Biosciences Inc. its own name
US, as the owner printed on each patent
3 published
Newest grantseach row opens the USPTO’s own copy
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Nov 27, 2025 | 2025/0361205 | ENZYME-CLEAVABLE METHADONE PRODRUGS AND METHODS OF USE THEREOF | Organic fine chemistry | Ensysce Biosciences Inc. |
| Jun 22, 2023 | 2023/0190697 | METHODS FOR TREATING VIRAL INFECTIONS WITH NAFAMOSTAT | Pharmaceuticals | Ensysce Biosciences Inc. |
| May 25, 2023 | 2023/0159441 | ENZYME-CLEAVABLE METHADONE PRODRUGS AND METHODS OF USE THEREOF | Organic fine chemistry | Ensysce Biosciences Inc. · patent 12,384,744 granted from it |
| Sep 15, 2022 | 2022/0287992 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | Pharmaceuticals | Ensysce Biosciences Inc. |
| Sep 15, 2022 | 2022/0287975 | MODIFIED RELEASE COMPOSITIONS OF NAFAMOSTAT AND METHODS OF USING SAME | Pharmaceuticals | Ensysce Biosciences Inc. |
| Jun 9, 2022 | 2022/0175699 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | Pharmaceuticals | Ensysce Biosciences Inc. |
| Feb 8, 2018 | 2018/0036374 | Single Walled Carbon Nanotube Polynucleotide Complexes and Methods Related Thereto | Pharmaceuticals | Ensysce Biosciences Inc. |
| Aug 11, 2016 | 2016/0228544 | Single Walled Carbon Nanotube Polynucleotide Complexes and Methods Related Thereto | Pharmaceuticals | Ensysce Biosciences Inc. |
| Jan 5, 2012 | 2012/0003278 | SINGLE-WALLED CARBON NANOTUBE/SIRNA COMPLEXES AND METHODS RELATED THERETO | Pharmaceuticals | Ensysce Biosciences Inc. · patent 8,772,258 granted from it |
| Feb 24, 2011 | 2011/0045031 | Use of Buckysome or Carbon Nanotube for Drug Delivery | Pharmaceuticals | Ensysce Biosciences Inc. |
What it applied for, 2024 to 2025: Organic fine chemistry 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.